Close

Aratana Therapeutics (PETX) Reports Study Results for AT-016

December 15, 2017 4:19 PM EST Send to a Friend
Aratana Therapeutics, Inc. (NASDAQ: PETX) has received top-line pivotal field effectiveness study results for AT-016, an investigational adipose-derived allogeneic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login